Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
The Lancet Global Health
IF
15.87
Papers
1817
Papers 1896
1 page of 190 pages (1,896 results)
Newest
Published in The Lancet Global Health 15.87
Ewen Liu (Wake Forest University), Juliet Iwelunmor4
Estimated H-index: 4
(SLU: Saint Louis University)
+ -3 AuthorsPascal Launois
Published on Jul 1, 2019in The Lancet Global Health 15.87
D.S. Ediriweera4
Estimated H-index: 4
(University of Kelaniya),
Sharmini Gunawardena6
Estimated H-index: 6
(UoC: University of Colombo)
+ 7 AuthorsNilanthi de Silva16
Estimated H-index: 16
(University of Kelaniya)
Summary Background In Sri Lanka, deworming programmes for soil-transmitted helminth infections became an integral part of school health in the 1960s, whereas routine antenatal deworming with mebendazole started in the 1980s. A 2003 national soil-transmitted helminth survey done among schoolchildren found an overall prevalence of 6·9%. In our study, we aimed to reassess the national prevalence of soil-transmitted helminth infections to enable implementation of a more focused control programme tha...
Published on Jul 1, 2019in The Lancet Global Health 15.87
David Tordrup8
Estimated H-index: 8
(UU: Utrecht University),
Yvan Hutin26
Estimated H-index: 26
+ 7 AuthorsGottfried Hirnschall14
Estimated H-index: 14
Summary Background The World Health Assembly calls for elimination of viral hepatitis as a public health threat by 2030 (ie, −90% incidence and −65% mortality). However, WHO's 2017 cost projections to achieve health-related Sustainable Development Goals did not include the resources needed for hepatitis testing and treatment. We aimed to estimate the incremental commodity cost of adding scaled up interventions for testing and treatment of hepatitis to WHO's investment scenarios. Methods We added...
Published in The Lancet Global Health 15.87
Raja Dhar4
Estimated H-index: 4
(Fortis Healthcare),
Sheetu Singh1
Estimated H-index: 1
+ -3 AuthorsArjun Padmanabhan1
Estimated H-index: 1
Summary Background Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to cohorts from Europe and the USA, with few data from low-income and middle-income countries. We therefore aimed to describe the characteristics, severity of disease, microbiology, and treatment of patients with bronchiectasis in India. Methods The Indian bronchiectasis registry is a multicentre, prospective, observational cohort study. Adult patients (≥18 years) with CT-confi...
Published on Jul 1, 2019in The Lancet Global Health 15.87
Graham Cooke33
Estimated H-index: 33
(Imperial College London),
Timothy B. Hallett43
Estimated H-index: 43
(Medical Research Council)
Published in The Lancet Global Health 15.87
Alex Smolak2
Estimated H-index: 2
(Cornell University),
Hiam Chemaitelly14
Estimated H-index: 14
(Cornell University)
+ -3 AuthorsLaith J. Abu-Raddad42
Estimated H-index: 42
(Khalifa University)
Summary Background The epidemiology of Chlamydia trachomatis in the Middle East and north Africa is poorly understood. We aimed to provide a comprehensive epidemiological assessment of C trachomatis infection in the Middle East and north Africa. Methods We did a systematic review of C trachomatis infection as well as a meta-analysis and meta-regression of C trachomatis prevalence. We searched PubMed and Embase, as well as regional and national databases up to March 13, 2019, using broad search t...
Published in The Lancet Global Health 15.87
Bryony Simmons6
Estimated H-index: 6
(Imperial College London),
Graham Cooke33
Estimated H-index: 33
(Imperial College London),
Marisa Miraldo12
Estimated H-index: 12
(Imperial College London)
Summary Background Voluntary licences are increasingly being used to expand access to patented essential medicines in low-income and middle-income countries (LMICs). Since 2014, non-exclusive voluntary licences have been issued by Gilead and Bristol-Myers Squibb for key drugs for hepatitis C virus (HCV) infection. We aimed to evaluate the effect of these licences on access to HCV treatment. Methods We conducted a difference-in-differences analysis, exploiting the staggered and selective introduc...
12345678910